Moderna, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
MRNA Company Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
MRNA Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view MRNA Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
$MRNA is featured in our Lobbying Spending Growth strategy.
See All StrategiesAll
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of MRNA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by MRNA's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of MRNA in WallStreetBets Daily Discussion
MRNA News
Recent insights relating to MRNA
CNBC Recommendations
Recent picks made for MRNA stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in MRNA
Corporate Flights
Flights by private jets registered to MRNA
Our Analysis